Vectus Biosystems (ASX:VBS) Total Liabilities: A$1.27 Mil (As of Dec. 2025)


ASX:VBS Vectus Biosystems Ltd ASX:VBS
18 GF Score
Price A$0.13
! 2 Warning Signs
View Full Analysis

What is Vectus Biosystems Total Liabilities?

Vectus Biosystems ASX:VBS 18 Total Liabilities is A$1.27 Mil as of Dec. 2025. GuruFocus rates ASX:VBS with a GF Score™ of 18/100. The stock has 2 warning signs investors should review.

Vectus Biosystems's Total Liabilities for the quarter that ended in Dec. 2025 was A$1.27 Mil.

Vectus Biosystems's quarterly Total Liabilities increased from Dec. 2024 (A$0.83 Mil) to Jun. 2025 (A$1.04 Mil) and increased from Jun. 2025 (A$1.04 Mil) to Dec. 2025 (A$1.27 Mil).

Vectus Biosystems's annual Total Liabilities declined from Jun. 2023 (A$1.11 Mil) to Jun. 2024 (A$0.54 Mil) but then increased from Jun. 2024 (A$0.54 Mil) to Jun. 2025 (A$1.04 Mil).

Vectus Biosystems Total Liabilities Historical Data

* Premium members only.

The historical data trend for Vectus Biosystems's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vectus Biosystems Total Liabilities Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.87 7.47 1.11 0.54 1.04

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.54 0.83 1.04 1.27
ASX:VBS
18GF Score
Vectus Biosystems Ltd ASX:VBS
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectus Biosystems Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vectus Biosystems's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.836+(0.2+-5.2909066017293E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.003+0)
=1.04

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=0.783--0.257
=1.04

Vectus Biosystems's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.797+(0.467+0.0039999999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.27

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=0.462--0.806
=1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$1.27 Mil mean?
Vectus Biosystems (ASX:VBS) has a Total Liabilities of A$1.27 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vectus Biosystems and its competitors.
Is Vectus Biosystems' Total Liabilities too high?
Vectus Biosystems' current Total Liabilities is A$1.27 Mil. Overall, Vectus Biosystems has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' Total Liabilities compare to VRTX and REGN?
Vectus Biosystems' Total Liabilities of A$1.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vectus Biosystems and its competitors. Vectus Biosystems's current Total Liabilities is A$1.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current Total Liabilities of A$1.27 Mil. The current Total Liabilities is A$1.27 Mil. Vectus Biosystems' overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current Total Liabilities is A$1.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vectus Biosystems Business Description

Address 26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
18GF Score

Get the complete analysis for ASX:VBS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price